Matthew W. McClure - 27 Apr 2022 Form 3 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
Chief Medical Officer
Signature
/s/ Lucinda Y. Quan, as attorney-in fact for Matthew W. McClure
Issuer symbol
ALGS
Transactions as of
27 Apr 2022
Net transactions value
$0
Form type
3
Filing time
06 May 2022, 16:12:29 UTC
Next filing
11 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ALGS Common Stock 91,204 27 Apr 2022 See footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ALGS Stock Option (Right to Buy) 27 Apr 2022 Common Stock 53,648 $3.45 Direct F2
holding ALGS Stock Option (Right to Buy) 27 Apr 2022 Common Stock 255,626 $16.18 Direct F3
holding ALGS Stock Option (Right to Buy) 27 Apr 2022 Common Stock 92,000 $3.06 Direct F4
holding ALGS Stock Option (Right to Buy) 27 Apr 2022 Common Stock 23,000 $3.06 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Matthew Wright McClure and Elizabeth Maureen McClure Revocable Trust.
F2 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 20, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F3 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from December 1, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F4 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 4, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F5 100% of the shares subject to the option will be fully vested and exercisable on February 4, 2025.